

# MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

View Online



1.

Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE.

2.

Type 2 diabetes in adults: management | Guidance and guidelines | NICE.

3.

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes  
Systematic review and mixed-treatment comparison analysis.

4.

Obesity: identification, assessment and management | Guidance and guidelines | NICE.

5.

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International  
Federation on Ageing.  
<https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>.

6.

NHS Evidence: an introduction.

7.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. Textbook of Diabetes. (John Wiley & Sons, Incorporated, 2016).

8.

Holt, R. I. G. Textbook of diabetes. (Wiley-Blackwell, 2010).

9.

Atkinson, M. A. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine **2**, a007641–a007641 (2012).

10.

Jelinek, H. F., Stranieri, A., Yatsko, A. & Venkatraman, S. Data analytics identify glycosylated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. Computers in Biology and Medicine **75**, 90–97 (2016).

11.

S M Attard. Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. Nutrition & Diabetes **5**, (2015).

12.

Samuel, V. T. & Shulman, G. I. Integrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell **148**, 852–871 (2012).

13.

Beverly M Shields. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open **5**, (2015).

14.

Zaccardi, F., Webb, D. R., Yates, T. & Davies, M. J. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal* **92**, 63–69 (2016).

15.

Anthony H. Barnett, Jenny Grice. *New Mechanisms in Glucose Control*. (BMJ Books; 1 edition, 2013).

16.

Gregg, E. W. The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. *Diabetes Care* (2017) doi:10.2337/dci16-0055.

17.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

18.

Holt, R. I. G. *Textbook of diabetes*. (Wiley-Blackwell, 2010).

19.

Copeland, K. C. et al. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS* **131**, 364–382 (2013).

20.

Kenneth Hodson. Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine* **3**, (2010).

21.

Latika Sahu. Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine* **2**, (2009).

22.

Schwartz, S. S. et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the  $\beta$ -Cell-Centric Classification Schema. *Diabetes Care* **39**, 179–186 (2016).

23.

Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O. & Prentki, M. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes* **64**, 673–686 (2015).

24.

Gale, E. A. Is type 2 diabetes a category error? *The Lancet* **381**, 1956–1957 (2013).

25.

Moreno-Castilla, C., Mauricio, D. & Hernandez, M. Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports* **16**, (2016).

26.

Noctor, E. & Dunne, F. Postnatal testing following gestational diabetes. *The Lancet Diabetes & Endocrinology* **3**, 761–762 (2015).

27.

Birkeland, K. I. Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology* **3**, 752–753 (2015).

28.

Rinki Murphy. Monogenic diabetes and pregnancy. *Obstetric Medicine* **8**, (2015).

29.

Stewart, Z. A. et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine* **375**, 644–654 (2016).

30.

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). <https://www.nice.org.uk/guidance/ng3>.

31.

Jones, A. G. & Hattersley, A. T. The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine* **30**, 803–817 (2013).

32.

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care.  
<http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>.

33.

Brown, J. et al. Lifestyle interventions for the treatment of women with gestational diabetes. in *Cochrane Database of Systematic Reviews* (John Wiley & Sons, Ltd, 1996). doi:10.1002/14651858.CD011970.pub2.

34.

Rasouli, B. et al. Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. *Diabetic Medicine* **34**, 1259–1263 (2017).

35.

Davies, M., Dahl, D., Heise, T., Kiljanski, J. & Mathieu, C. Introduction of biosimilar insulins in Europe. *Diabetic Medicine* **34**, 1340–1353 (2017).

36.

Perrin, N. E., Davies, M. J., Robertson, N., Snoek, F. J. & Khunti, K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine* **34**, 1508–1520 (2017).

37.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

38.

Holt, R. I. G. *Textbook of diabetes*. (Wiley-Blackwell, 2010).

39.

Standards of Medical Care in Diabetes--2015: Summary of Revisions. *Diabetes Care* **38**, S4–S4 (2015).

40.

A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the anglo-Danish-Dutch Study of intensive Treatment in People with Screen-Detected Diabetes in Primary care (ADDITION-Europe) study.

41.

Kamlesh Khunti. Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. *PLoS ONE* **10**, (2015).

42.

Tao, L. et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine* **32**, 907–919 (2015).

43.

Gray, L. J., Khunti, K., Wilmot, E. G., Yates, T. & Davies, M. J. External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice* **104**, 451–458 (2014).

44.

Gray, L. J. et al. Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia* **55**, 3238–3244 (2012).

45.

Inzucchi, S. E. et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* **38**, 140–149 (2015).

46.

Guidelines. <https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>.

47.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

48.

Holt, R. I. G. *Textbook of diabetes*. (Wiley-Blackwell, 2010).

49.

Holt, R. I. G. Textbook of diabetes. (Wiley-Blackwell, 2010).

50.

Davies, M. J. et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ* **336**, 491–495 (2008).

51.

Johnston, B. C. et al. Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA* **312**, (2014).

52.

Steven, S. et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care* **39**, 808–815 (2016).

53.

Steven, S. & Taylor, R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine* **32**, 1149–1155 (2015).

54.

Amy Kennedy. Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE* **8**, (2013).

55.

Chimen, M. et al. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia* **55**, 542–551 (2012).

56.



Umpierre, D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA<sub>1c</sub> Levels in Type 2 Diabetes. *JAMA* **305**, (2011).

57.

Avery, L., Flynn, D., van Wersch, A., Sniehotta, F. F. & Trenell, M. I. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care* **35**, 2681–2689 (2012).

58.

Barry, V. W. et al. Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases* **56**, 382–390 (2014).

59.

Qin, L., Knol, M. J., Corpeleijn, E. & Stolk, R. P. Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology* **25**, 5–12 (2010).

60.

Lee, I.-M. Physical Activity and Weight Gain Prevention. *JAMA* **303**, (2010).

61.

John M Jakicic. Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition* **82**, 226S-229S (2005).

62.

Heinonen, I. et al. Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open* **3**, (2013).

63.

Sallis, J. F. et al. Progress in physical activity over the Olympic quadrennium. *The Lancet*

**388**, 1325–1336 (2016).

64.

Yeh, J. S., Kushner, R. F. & Schiff, G. D. Obesity and Management of Weight Loss. *New England Journal of Medicine* **375**, 1187–1189 (2016).

65.

Henson, Joseph. Associations of Sedentary Time with Fat Distribution in a High-Risk Population. (2014).

66.

The Eatwell Guide. (Public Health England, 2016).

67.

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008. <http://www.nice.org.uk/guidance/ta151>.

68.

Hadjiconstantinou, M. et al. Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research* **18**, (2016).

69.

Young-Hyman, D. et al. Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care* **40**, 287.1-287 (2017).

70.

Capehorn, M. et al. Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia ).

Diabetic Medicine (2017) doi:10.1111/dme.13357.

71.

Hartman, Y. A. W., Jansen, H. J., Hopman, M. T. E., Tack, C. J. & Thijssen, D. H. J. Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care* **40**, e120–e121 (2017).

72.

Hessler, D. M. et al. Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. *Diabetic Medicine* **34**, 1228–1234 (2017).

73.

Ferrari, M., Dal Cin, M. & Steele, M. Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. *Diabetic Medicine* **34**, 1546–1553 (2017).

74.

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. *Diabetes Care*.

75.

Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey.  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>.

76.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

77.

Holt, R. I. G. Textbook of diabetes. (Wiley-Blackwell, 2010).

78.

Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet* **380**, 475–483 (2012).

79.

Rizos, C. V., Kei, A. & Elisaf, M. S. The current role of thiazolidinediones in diabetes management. *Archives of Toxicology* **90**, 1861–1881 (2016).

80.

Nissen, S. E. & Wolski, K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine* **356**, 2457–2471 (2007).

81.

Tanner, M. Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine* **165**, (2016).

82.

Mishriky, B. M., Cummings, D. M. & Tanenberg, R. J. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice* **109**, 378–388 (2015).

83.

Bennett, W. L. et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine* **154**, (2011).

84.

Merlin C. Thomas. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy* **7**, (2016).

85.

Paul Craddy. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy* **5**, (2014).

86.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

87.

Holt, R. I. G. *Textbook of diabetes*. (Wiley-Blackwell, 2010).

88.

Ryder, B. et al. ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes* **30**, 388–391 (2013).

89.

Amori, R. E., Lau, J. & Pittas, A. G. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA* **298**, (2007).

90.

Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet* **374**, 39–47 (2009).

91.

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE.

92.

Buse, J. B. et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care* **33**, 1255–1261 (2010).

93.

Buse, J. B. et al. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine* **154**, (2011).

94.

Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A. & List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet* **375**, 2223–2233 (2010).

95.

Diamant, M. et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet* **375**, 2234–2243 (2010).

96.

Nauck, M. A., Meininger, G., Sheng, D., Terranella, L. & Stein, P. P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism* **9**, 194–205 (2007).

97.

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE.

98.

Marso, S. P. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine* (2016) doi:10.1056/NEJMoa1607141.

99.

Nauck, M. A. & Meier, J. J. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology* **4**, 525–536 (2016).

100.

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE.

101.

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013.  
<http://www.nice.org.uk/guidance/ta288>.

102.

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015.  
<https://www.nice.org.uk/guidance/ta248>.

103.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010.  
<https://www.nice.org.uk/guidance/ta203>.

104.

Marso, S. P. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **375**, 311–322 (2016).

105.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **375**, 1797–1799 (2016).

106.

Wanner, C. et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine* **375**, 323–334 (2016).

107.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine* **375**, 1799–1802 (2016).

108.

Courtney, H., Nayar, R., Rajeswaran, C. & Jandhyala, R. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* **Volume 10**, 79–87 (2017).

109.

Green, J. B. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **373**, 232–242 (2015).

110.

Rotz, M. E., Ganetsky, V. S., Sen, S. & Thomas, T. F. Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice* **69**, 531–549 (2015).

111.

Marso, S. P. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* **375**, 311–322 (2016).

112.



Levin, P. A., Nguyen, H., Wittbrodt, E. & Kim, S. C. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* **Volume 10**, 123–139 (2017).

113.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

114.

Holt, R. I. G. *Textbook of diabetes*. (Wiley-Blackwell, 2010).

115.

Leff, D. R. & Heath, D. Surgery for obesity in adulthood. *BMJ* **339**, b3402–b3402 (2009).

116.

Schauer, P. R. et al. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine* **366**, 1567–1576 (2012).

117.

Riddle, M. C. et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care* **36**, 2489–2496 (2013).

118.

Sjöström, L. et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine* **351**, 2683–2693 (2004).

119.

Persaud, S. J. & Jones, P. M. A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine* **375**, 1090–1092 (2016).

120.

Fagin, J. A. & Wells, S. A. Biologic and Clinical Perspectives on Thyroid Cancer. *New England Journal of Medicine* **375**, 1054–1067 (2016).

121.

National Obesity Observatory. <http://www.noo.org.uk>.

122.

Schauer, P. R. et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine* **376**, 641–651 (2017).

123.

Min, S. H., Yoon, J.-H., Hahn, S. & Cho, Y. M. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews* **33**, (2017).

124.

Dungan, K. M. et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet* **384**, 1349–1357 (2014).

125.

Nauck, M. et al. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care* **37**, 2149–2158 (2014).

126.

Schauer, P. R. et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine* **376**, 641–651 (2017).

127.

Bethel, M. A. et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Care* **40**, 494–501 (2017).

128.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

129.

Holt, R. I. G. *Textbook of diabetes*. (Wiley-Blackwell, 2010).

130.

Bergenstal, R. M. et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine* **363**, 311–320 (2010).

131.

Choudhary, P., Parrott, N. R., Birtles, L. & Rutter, M. K. Islet cell transplantation: current status in the UK (2012). *Practical Diabetes* **29**, 280–285 (2012).

132.

Pickup, J. C. Insulin-Pump Therapy for Type 1 Diabetes Mellitus. *New England Journal of Medicine* **366**, 1616–1624 (2012).

133.

Srinivasan, P., Huang, G. C., Amiel, S. A. & Heaton, N. D. Islet cell transplantation. *Postgraduate Medical Journal* **83**, 224–229 (2007).

134.

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010.  
<https://www.nice.org.uk/guidance/ta203>.

135.

Villani, M., de Courten, B. & Zoungas, S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine* **34**, 1205–1211 (2017).

136.

Dhatariya, K. K., Skedgel, C. & Fordham, R. The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine* **34**, 1361–1366 (2017).

137.

Leelarathna, L. et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine* **34**, 1372–1379 (2017).

138.

Yates, T. & Davies, M. J. Physical activity and Type 1 diabetes: an underused therapy. *Diabetic Medicine* **34**, 1498–1499 (2017).

139.

Narendran, P. et al. Exercise to preserve  $\beta$ -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. *Diabetic Medicine* **34**, 1521–1531 (2017).

140.

Holt, R. I. G., Cockram, C., Flyvbjerg, A. & Goldstein, B. J. *Textbook of Diabetes*. (John Wiley & Sons, Incorporated, 2016).

141.

Holt, R. I. G. Textbook of diabetes. (Wiley-Blackwell, 2010).

142.

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. Journal of diabetes science and technology (Online) **3**,.

143.

Minimizing Hypoglycemia in Diabetes: Table 1. Diabetes Care **38**, 1583–1591 (2015).

144.

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics.  
[http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh\\_082200](http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publication/sandstatistics/publications/publicationspolicyandguidance/dh_082200).

145.

Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009. <https://www.nice.org.uk/guidance/cg76>.

146.

Grammes, J., Stock, W., Mann, C. G., Flynn, E. M. & Kubiak, T. Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. Diabetic Medicine (2017) doi:10.1111/dme.13506.

147.

Sivasubramaniyam, S., Amiel, S. A. & Choudhary, P. Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. Diabetic Medicine **34**, 1456–1460 (2017).

148.

Vloemans, A. F. et al. Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine* **34**, 1470–1476 (2017).

149.

Harman-Boehm, I. Continuous glucose monitoring in type 2 diabetes. *Diabetes Research and Clinical Practice* **82**, S118–S121 (2008).

150.

Bailey, Stephen. *Academic Writing : A Handbook for International Students*.

151.

Creame, P. & Lea, M. R. *Writing At University: A Guide For Students*. (McGraw-Hill Education, 2008).